Myocardial Revascularization by Percutaneous Coronary Intervention: Past, Present, and the Future

Current Problems in Cardiology

Volumn 36, Issue 10, 2011, Pages 375-401

  Singh, Inder M ^a   Holmes, David R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CARDIOVASCULAR AGENT; CLOPIDOGREL; EVEROLIMUS; HEPARIN; HIRULOG; PACLITAXEL; PRASUGREL; RAPAMYCIN; TICAGRELOR; TIROFIBAN; UNCLASSIFIED DRUG; ZATROLIMUS;

ACUTE CORONARY SYNDROME; AORTA BIFURCATION; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC TOTAL OCCLUSION; CLINICAL PRACTICE; CLINICAL RESEARCH; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG ELUTING STENT; DRUG MEGADOSE; EDUCATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYBRID PROCEDURE; INTERMETHOD COMPARISON; LEFT MAIN CORONARY LESION; LOW DRUG DOSE; MULTIVESSEL DISEASE; NON ST ELEVATION ACUTE CORONARY SYNDROME; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE CORONARY SYNDROME; SURGICAL TECHNIQUE; TRAINING; VASCULAR DISEASE; VEIN GRAFT DISEASE;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; EQUIPMENT DESIGN; FORECASTING; HEART DISEASES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYOCARDIAL REVASCULARIZATION; PATIENT SELECTION; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052289120     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2011.05.005     Document Type: Article

References (137)

1. Baim D.S. Grossman's Cardiac Catheterization, Angiography, and Intervention 2005, 992.
2. Holmes D.R., Williams D.O. Catheter-based treatment of coronary artery disease: Past, present, and future. Circ Cardiovasc Interv 2008, 1:60-73.
3. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978, 1:263.
4. Grüntzig A., Kumpe D.A. Technique of percutaneous transluminal angioplasty with the Grüntzig ballon catheter. AJR Am J Roentgenol 1979, 132:547-552.
5. Grüntzig A.R., Senning A., Siegenthaler W.E. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979, 301:61-68.
6. Sigwart U., Puel J., Mirkovitch V., et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987, 316:701-706.
7. Holmes D.R., Vlietstra R.E., Fisher L.D., et al. Follow-up of patients from the coronary artery surgery study (CASS) potentially suitable for percutaneous transluminal coronary angioplasty. Am Heart J 1983, 106:981-988.
8. Vlietstra R.E., Holmes D.R., Smith H.C., et al. Percutaneous transluminal coronary angioplasty: initial Mayo clinic experience. Mayo Clin Proc 1981, 56:287-293.
9. Holmes D.R., Holubkov R., Vlietstra R.E., et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988, 12:1149-1155.
10. Iyengar S., Gray W.A. Use of magnetic guidewire navigation in the treatment of lower extremity peripheral vascular disease: report of the first human clinical experience. Catheter Cardiovasc Interv 2009, 73:739-744.
11. King S.B., Yeh W., Holubkov R., et al. Balloon angioplasty versus new device intervention: Clinical outcomes. A comparison of the nhlbi PTCA and NACI registries. J Am Coll Cardiol 1998, 31:558-566.
12. Elliott J.M., Berdan L.G., Holmes D.R., et al. One-year follow-up in the coronary angioplasty versus excisional atherectomy trial (caveat I). Circulation 1995, 91:2158-2166.
13. Holmes D.R., Topol E.J., Califf R.M., et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. Caveat-II investigators. Circulation 1995, 91:1966-1974.
14. Whitlow P.L., Bass T.A., Kipperman R.M., et al. Results of the study to determine rotablator and transluminal angioplasty strategy (stratas). Am J Cardiol 2001, 87:699-705.
15. Klein L.W., Litvack F., Holmes D., et al. Six month outcome and determinants of adverse clinical events after successful excimer laser coronary angioplasty. ELCA A.I.S. Multicenter registry. J Invasive Cardiol 1995, 7:191-199.
16. Kuntz R.E., Gibson C.M., Nobuyoshi M., et al. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993, 21:15-25.
17. Salam A.M., Al Suwaidi J., Holmes D.R. Drug-eluting coronary stents. Curr Probl Cardiol 2006, 31:8-119.
18. Daemen J., Serruys P.W. Drug-eluting stent update 2007: Part II: Unsettled issues. Circulation 2007, 116:961-968.
19. Marroquin O.C., Selzer F., Mulukutla S.R., et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008, 358:342-352.
20. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370:937-948.
21. Holmes D.R., Leon M.B., Moses J.W., et al. Analysis of 1-year clinical outcomes in the Sirius trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004, 109:634-640.
22. Holmes D.R., Teirstein P., Satler L., et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the sisr randomized trial. JAMA 2006, 295:1264-1273.
23. Stone G.W., Ellis S.G., O'Shaughnessy C.D., et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS v ISR randomized trial. JAMA 2006, 295:1253-1263.
24. Singh I.M., Filby S.J., Sakr F.E., et al. Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis. Catheter Cardiovasc Interv 2010, 75:338-342.
25. Singh I.M., Filby S.J., El Sakr F., et al. Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis. Catheter Cardiovasc Interv 2010, 76:257-262.
26. Chen M.S., John J.M., Chew D.P., et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006, 151:1260-1264.
27. Holmes D.R., Kereiakes D.J., Laskey W.K., et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol 2007, 50:109-118.
28. Stone G.W., Ellis S.G., Colombo A., et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007, 115:2842-2847.
29. Laskey W.K., Yancy C.W., Maisel W.H. Thrombosis in coronary drug-eluting stents: Report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, December 7-8, 2006. Circulation 2007, 115:2352-2357.
30. Mauri L., Hsieh W.H., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007, 356:1020-1029.
31. Holmes D.R., Kereiakes D.J., Garg S., et al. Stent thrombosis. J Am Coll Cardiol 2010, 56:1357-1365.
32. Doyle B., Rihal C.S., O'Sullivan C.J., et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007, 116:2391-2398.
33. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007, 115:2435-2441.
34. Garg S., Serruys P.W. Coronary stents: Looking forward. J Am Coll Cardiol 2010, 56:S43-S78.
35. Parsonage E., Girton T., Knapp D. Biomaterial considerations for drug-eluting stents. Conf Proc IEEE Eng Med Biol Soc 2009, 2009:2416-2417.
36. Sharma S., Kukreja N., Christopoulos C., et al. Drug-eluting balloon: New tool in the box. Exp Rev Med Dev 2010, 7:381-388.
37. De Labriolle A., Pakala R., Bonello L., et al. Paclitaxel-eluting balloon: from bench to bed. Catheter Cardiovasc Interv 2009, 73:643-652.
38. Dill T., Schächinger V., Rolf A., et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute st-segment elevation myocardial infarction: Results of the reinfusion of enriched progenitor cells and infarct remodeling in acute myocardial infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 2009, 157:541-547.
39. Mansour S., Roy D.C., Bouchard V., et al. Compare-ami trial: Comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design. Cardiovasc J Trans Resources 2010, 3:153-159.
40. Simari R.D., Moye L.A., Skarlatos S.I., et al. Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored cardiovascular cell therapy research network (CCTRN). Cardiovasc J Trans Resources 2010, 3:30-36.
41. Sürder D., Schwitter J., Moccetti T., et al. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the Swiss multicenter intracoronary stem cells study in acute myocardial infarction (Swiss-AMI). Am Heart J 2010, 160:58-64.
42. Traverse J.H., Henry T.D., Vaughan D.E., et al. LateTIME: a Phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J 2010, 37:412-420.
43. Rao S.V., Ou F.S., Wang T.Y., et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the national cardiovascular data registry. JACC Cardiovasc Interv 2008, 1:379-386.
44. Rao S.V., Cohen M.G., Kandzari D.E., et al. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. J Am Coll Cardiol 2010, 55:2187-2195.
45. Doyle B.J., Ting H.H., Bell M.R., et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv 2008, 1:202-209.
46. Amoroso G., Kiemeneij F. Transradial access for primary percutaneous coronary intervention: the next standard of care?. Heart 2010, 96:1341-1344.
47. Kushner F.G., Hand M., Smith S.C., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 54:2205-2241.
48. Ting H.H., Yang E.H., Rihal C.S. Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction. Ann Intern Med 2006, 145:610-617.
49. Rihal C.S., Jaffe A.S., Holmes D.R., et al. Percutaneous coronary intervention vs thrombolysis for st-elevation myocardial infarction. JAMA 2007, 297:1313. [Author reply 1314-5].
50. Ting H.H., Rihal C.S., Gersh B.J., et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI protocol. Circulation 2007, 116:729-736.
51. Bradley E.H., Nallamothu B.K., Herrin J., et al. National efforts to improve door-to-balloon time results from the door-to-balloon alliance. J Am Coll Cardiol 2009, 54:2423-2429.
52. Cannon C.P. Strategies and therapies for reducing ischemic and vascular events (STRIVE): updated standing orders for st-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction. Crit Pathw Cardiol 2010, 9:55-81.
53. Holmes D.R., Bell M.R., Gersh B.J., et al. Systems of care to improve timeliness of reperfusion therapy for st-segment elevation myocardial infarction during off hours: the Mayo Clinic STEMI protocol. JACC Cardiovasc Interv 2008, 1:88-96.
54. Kereiakes D.J. Specialized centers and systems for heart attack care. Am Heart Hosp J 2008, 6:14-20.
55. Khawaja F.J., Ting H.H. Quality dimensions of primary percutaneous coronary intervention: timeliness, access, and availability. Circulation 2009, 120:2411-2413.
56. Krumholz H.M., Bradley E.H., Nallamothu B.K., et al. A campaign to improve the timeliness of primary percutaneous coronary intervention: Door-to-balloon: an alliance for quality. JACC Cardiovasc Interv 2008, 1:97-104.
57. Ellis S.G., Tendera M., de Belder M.A., et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008, 358:2205-2217.
58. Di Lorenzo E., Sauro R., Varricchio A., et al. Long-term outcome of drug-eluting stents compared with bare metal stents in st-segment elevation myocardial infarction: Results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in primary angioplasty (PASEO) randomized trial. Circulation 2009, 120:964-972.
59. Stone G.W., Lansky A.J., Pocock S.J., et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009, 360:1946-1959.
60. Violini R., Musto C., De Felice F., et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with st-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. J Am Coll Cardiol 2010, 55:810-814.
61. Shishehbor M.H., Amini R., Oliveria L.P., et al. Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008, 1:227-232.
62. Vlaar P.J., Rihal C.S., Singh M., et al. Safety and efficacy of drug-eluting stent for st-segment elevation myocardial infarction in an unselected consecutive cohort. Catheter Cardiovasc Interv 2008, 71:764-769.
63. Stone G.W., Webb J., Cox D.A., et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 2005, 293:1063-1072.
64. Srinivasan M., Rihal C., Holmes D.R., et al. Adjunctive thrombectomy and distal protection in primary percutaneous coronary intervention: Impact on microvascular perfusion and outcomes. Circulation 2009, 119:1311-1319.
65. Ali A., Cox D., Dib N., et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol 2006, 48:244-252.
66. Svilaas T., Vlaar P.J., van der Horst I.C., et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008, 358:557-567.
67. Vlaar P.J., Svilaas T., van der Horst I.C., et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study. Lancet 2008, 371:1915-1920.
68. Lønborg J., Kelbaek H., Vejlstrup N., et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv 2010, 3:34-41.
69. Desai N.R., Bhatt D.L. The state of periprocedural antiplatelet therapy after recent trials. JACC Cardiovasc Interv 2010, 3:571-583.
70. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
71. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
72. Steinhubl S., Roe M.T. Optimizing platelet p2y12 inhibition for patients undergoing pci. Cardiovasc Drug Rev 2007, 25:188-203.
73. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
74. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
75. Mehta S.R., Bassand J.P., Chrolavicius S., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363:930-942.
76. Mehta S.R., Tanguay J.F., Eikelboom J.W., et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (current-oasis 7): a randomised factorial trial. Lancet 2010, 376:1233-1243.
77. Bainey K.R., Mehta S.R. Aspirin for acute coronary syndromes: have we learned the correct dose yet?. Curr Cardiol Rep 2010, 12:344-347.
78. Gibson C.M., Murphy S.A., Montalescot G., et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the extract-TIMI 25 trial. J Am Coll Cardiol 2007, 49:2238-2246.
79. Schömig A., Kastrati A., Dirschinger J., et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus thrombolysis for occluded coronary arteries in patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000, 343:385-391.
80. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001, 344:1895-1903.
81. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001, 344:1888-1894.
82. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
83. Ting H.H., Krumholz H.M., Bradley E.H., et al. Implementation and integration of prehospital ecgs into systems of care for acute coronary syndrome: a scientific statement from the American Heart Association interdisciplinary council on quality of care and outcomes research, emergency cardiovascular care committee, council on cardiovascular nursing, and council on clinical cardiology. Circulation 2008, 118:1066-1079.
84. Bhatt D.L. To cath or not to cath: that is no longer the question. JAMA 2005, 293:2935-2937.
85. Bavry A.A., Kumbhani D.J., Rassi A.N., et al. Benefit of early invasive therapy in acute coronary syndromes: A meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006, 48:1319-1325.
86. Bhatt D.L., Roe M.T., Peterson E.D., et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from the crusade quality improvement initiative. JAMA 2004, 292:2096-2104.
87. de Winter R.J., Windhausen F., Cornel J.H., et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005, 353:1095-1104.
88. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009, 360:2176-2190.
89. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
90. Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009, 361:2318-2329.
91. Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009, 361:2330-2341.
92. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable anginanon-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N Engl J Med 1998, 338:1488-1497.
93. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The Pursuit Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy. N Engl J Med 1998, 339:436-443.
94. Hamm C.W., Heeschen C., Goldmann B., et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. C7E3 Fab antiplatelet therapy in unstable refractory angina (capture) study investigators. N Engl J Med 1999, 340:1623-1629.
95. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216.
96. Holmes D.R., Gersh B.J., Whitlow P., et al. Percutaneous coronary intervention for chronic stable angina: a reassessment. JACC Cardiovasc Interv 2008, 1:34-43.
97. Coylewright M., Blumenthal R.S., Post W. Placing courage in context: review of the recent literature on managing stable coronary artery disease. Mayo Clin Proc 2008, 83:799-805.
98. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without pci for stable coronary disease. N Engl J Med 2007, 356:1503-1516.
99. Shaw L.J., Berman D.S., Maron D.J., et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 2008, 117:1283-1291.
100. Singh I.M., Shishehbor M.H., Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
101. Hoye A., van Domburg R.T., Sonnenschein K., et al. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002. Eur Heart J 2005, 26:2630-2636.
102. Prasad A., Rihal C.S., Lennon R.J., et al. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the mayo clinic. J Am Coll Cardiol 2007, 49:1611-1618.
103. Stone G.W., Kandzari D.E., Mehran R., et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: Part I. Circulation 2005, 112:2364-2372.
104. Suero J.A., Marso S.P., Jones P.G., et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 2001, 38:409-414.
105. Weisz G., Moses J.W. Contemporary principles of coronary chronic total occlusion recanalization. Catheter Cardiovasc Interv 2010, 75(suppl 1):S21-S27.
106. Fefer P., Carlino M., Strauss B.H. Intraplaque therapies for facilitating percutaneous recanalization of chronic total occlusions. Can J Cardiol 2010, 26(suppl A):32A-36A.
107. Al Suwaidi J., Yeh W., Cohen H.A., et al. Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry). Am J Cardiol 2001, 87:1139-1144.
108. Sharma S.K., Sweeny J., Kini A.S. Coronary bifurcation lesions: a current update. Cardiol Clin 2010, 28:55-70.
109. Colombo A., Bramucci E., Saccà S., et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the cactus (coronary bifurcations: application of the crushing technique using sirolimus-eluting stents) study. Circulation 2009, 119:71-78.
110. Behan M.W., Holm N.R., Curzen N.P., et al. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic bifurcation study and the British bifurcation coronary study. Circ Cardiovasc Interv 2011, 4:57-64.
111. Ormiston J., Webster M., El-Jack S., et al. The AST petal dedicated bifurcation stent: first-in-human experience. Catheter Cardiovasc Interv 2007, 70:335-340.
112. Grube E., Buellesfeld L., Neumann F.J., et al. Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am J Cardiol 2007, 99:1691-1697.
113. El-Menyar A.A., Al Suwaidi J., Holmes D.R. Left main coronary artery stenosis: state-of-the-art. Curr Probl Cardiol 2007, 32:103-193.
114. Biondi-Zoccai G.G., Lotrionte M., Moretti C., et al. A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. Am Heart J 2008, 155:274-283.
115. Serruys P.W., Morice M.C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009, 360:961-972.
116. Seung K.B., Park D.W., Kim Y.H., et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 2008, 358:1781-1792.
117. Teirstein P.S. Percutaneous revascularization is the preferred strategy for patients with significant left main coronary stenosis. Circulation 2009, 119:1021-1033.
118. Morice M.C., Serruys P.W., Kappetein A.P., et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. Circulation 2010, 121:2645-2653.
119. Hannan E.L., Racz M.J., Walford G., et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005, 352:2174-2183.
120. Mercado N., Wijns W., Serruys P.W., et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg 2005, 130:512-519.
121. Hannan E.L., Wu C., Walford G., et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008, 358:331-341.
122. From A.M., Al Badarin F.J., Cha S.S., et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis of data from the ARTS II, CARDIA, ERACI III, and SYNTAX studies and systematic review of observational data. EuroIntervention 2010, 6:269-276.
123. Farkouh M.E., Dangas G., Leon M.B., et al. Design of the future revascularization evaluation in patients with diabetes mellitus: Optimal management of multivessel disease (FREEDOM) trial. Am Heart J 2008, 155:215-223.
124. Hannan E.L., Racz M., Holmes D.R., et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006, 113:2406-2412.
125. Byrne J.G., Leacche M., Vaughan D.E., et al. Hybrid cardiovascular procedures. JACC Cardiovasc Interv 2008, 1:459-468.
126. Leacche M., Umakanthan R., Zhao D.X., et al. Surgical update: hybrid procedures, do they have a role?. Circ Cardiovasc Interv 2010, 3:511-518.
127. Morís C., Lozano I., Martín M., et al. Embolic protection devices in saphenous percutaneous intervention. EuroIntervention 2009, 5(suppl D):D45-D50.
128. Brilakis E.S., Lichtenwalter C., de Lemos J.A., et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009, 53:919-928.
129. Lee M.S., Yang T., Kandzari D.E., et al. Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention. Am J Cardiol 2010, 105:1076-1082.
130. Shishehbor M.H., Hawi R., Singh I.M., et al. Drug-eluting versus bare-metal stents for treating saphenous vein grafts. Am Heart J 2009, 158:637-643.
131. Greelish J.P., Ailiwadi M., Balaguer J.M., et al. Combined percutaneous coronary intervention and valve surgery. Curr Opin Cardiol 2006, 21:113-117.
132. Umakanthan R., Leacche M., Petracek M.R., et al. Combined pci and minimally invasive heart valve surgery for high-risk patients. Curr Treat Options Cardiovasc Med 2009, 11:492-498.
133. Zhao D.X., Leacche M., Balaguer J.M., et al. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. J Am Coll Cardiol 2009, 53:232-241.
134. Jacobs A.K., Babb J.D., Hirshfeld J.W., et al. Task force 3: Training in diagnostic and interventional cardiac catheterization endorsed by the society for cardiovascular angiography and interventions. J Am Coll Cardiol 2008, 51:355-361.
135. Anand S.S., Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet 2011.
136. Franco M., Cooper R.S., Bilal U., et al. Challenges and opportunities for cardiovascular disease prevention. Am J Med 2011, 124:95-102.
137. Harrington R.A., Califf R.M., Hodgson P.K., et al. Careers for clinician investigators. Circulation 2009, 119:2945-2950.